tumor neuropeptide receptor imaging

Radionuclide-labeled tumor neuropeptide receptor imaging is the youngest and most dynamic branch of nuclear medicine. Receptor imaging of radionuclide-labeled ligands such as vasoactiveintestinal peptide (VIP) or somatostatin (SST) has demonstrated its clinical utility. Moreover, these imaging methods can also help to effectively treat tumors by providing the correct in vivo features of tumor receptor expression. Basic Information Specialist Category: Oncology Inspection Category: Radionuclide Applicable gender: whether men and women apply fasting: fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: Tumor somatostatin receptor imaging and treatment by positron-labeled octreotide has been used for thyroid cancer, gastrointestinal pancreatic neuroendocrine tumor, pheochromocytoma, small cell lung cancer and the like. It provides a new and effective method for the diagnosis of high- or high-mortal tumors such as gastrointestinal VIP receptor-positive tumors (gastrointestinal pancreatic tumors) and small cell lung cancer. Tips: Please check the expedition to the undergraduate room on the same day. Normal value Receptor imaging showed a negative result. Clinical significance Abnormal results: Tumor somatostatin receptor imaging and treatment with positron-labeled octreotide such as 18F, 11C, copper [64Cu] and gallium [68Ga] have been used in thyroid cancer, gastrointestinal pancreatic nerve Endocrine tumors, pheochromocytoma, small cell lung cancer, etc. 18F, 68Ga and other labeled vasoactive peptides (VIP) have good biological activity, and are gastrointestinal VIP receptor-positive tumors (gastrointestinal pancreatic tumors), small cell lung cancer, meningioma, multiple pathological types of breast cancer, The diagnosis of high- or high-mortal tumors such as neuroblastoma provides a new and effective method. People who need to be examined: Tumor patients and patients with related diseases need to be examined. Positive results may be diseases: pheochromocytoma, meningioma, thyroid cancer, neuroblastoma, small cell lung cancer precautions Forbidden before inspection: Please check the expedition to the department on the day of the examination. Requirements for examination: The patient should be at rest and use a sedative if necessary. Inspection process With positron emission tomography, the development of PET and PET/CT technology in recent years, positron-emitting radiopharmaceuticals occupy an important position and role in oncology research and clinical application. Not suitable for the crowd Inappropriate people: no special requirements. Adverse reactions and risks Nothing.